GNCAQ

0.00010.00%
MV

Marcela V. Maus

Member of Scientific Advisory Board

Dr. Marcela V. Maus M.D, Ph.D is Director of Umoja BioPharma, Inc. from March 2026. Dr. Maus is Scientific Advisor of LUMICKS B.V. Maus was Member of Scientific Advisory Board of AffyImmune Therapeutics, Inc. from 2025 until July 2025. Dr. Maus serves as Member of Scientific Advisory Board of CARGO Therapeutics, Inc. since December 2023. She is Member of Scientific & Clinical Advisory Board at A2 Biotherapeutics, Inc. from March 2023. She is Member of Scientific Advisory Board at MaxCyte, Inc. from March 2023. She served as Member of Medical Advisory Board at Targazyme, Inc. She serves as Member of the Scientific Advisory Board at MiNK Therapeutics, Inc. She served as Cell Therapy Scientific Advisory Board Member at Oncternal Therapeutics, Inc since November 2021 until July 2025. She serves as Member of Scientific Advisory Board at NexImmune, Inc. since May 2021. She served as Member of Scientific Advisory Board at IN8bio, Inc. until 2026. She served as Director at bluebird bio, Inc. since September 2021 until November 2021. She serves as Member of Scientific Advisory Board at Genocea Biosciences, Inc. She is a Director of Model T Bio since July 1, 2024. She was an Independent Director at 2seventy bio, Inc. since October 15, 2021 until May 13, 2025. She serves as Associate Professor at Harvard Medical School, the Paula O’Keefe Chair in Oncology. She is an Associate Member of the Broad Institute of Harvard and Massachusetts Institute of Technology ("MIT") and an Associate Member of the Ragon Institute of MGH, MIT and Harvard. Dr. Maus served as Member of Advisory Board at TCR2 Therapeutics Inc. until 2020. She served as Member of Scientific Advisory Board at Agenus Inc. until November 2021. She has been Member of Scientific Advisory Board at MicroMedicine, Inc. since November 2018. Dr. Maus serves as Director of Cellular Immunotherapy at the Massachusetts General Hospital in Boston. She has authored over 100 papers indexed in Pubmed and holds multiple NIH R01 grants and several Investigational New Drug Applications. She has been a Member of Clinical Advisory Board at Cellectis S. A. since March 7, 2017. She also serves on several scientific and clinical advisory boards for the biotechnology industry as well as external academic medical centers. Dr. Maus is a translational physician-scientist in the field of cancer immunology. Her laboratory focuses on the design, generation and use of innovative forms of immune cell engineering, including chimeric antigen receptors and investigates basic mechanisms of human immunology to design and test novel immune-based therapeutic interventions in vitro, in mouse models and in patients. She is a Member of the Center for Cancer Immunology and the Department of Medicine at MGH. Dr. Maus trained with pioneer Carl June, MD at the University of Pennsylvania and is a leader in the field of cancer immunology with expertise in T-cell immunotherapies. She is a board-certified hematologist-oncologist with extensive research expertise in all aspects of pre-clinical and clinical design and use of cell therapies and gene-modified T-cells for cancer. As a graduate student, she worked with Dr. Carl June on the biology of human T cell activation. She completed residency training in internal medicine at the University of Pennsylvania Health System and completed fellowship training in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center. Her research focuses on the pre-clinical development and clinical translation of engineered T cell therapies. Dr. Maus completed undergraduate studies at MIT and her MD and PhD at University of Pennsylvania. She also received a BS in Biology and Literature from Massachusetts Institute of Technology.

Positions